Candriam SCA’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.7M | Sell |
367,485
-893,976
| -71% | -$48.5M | 0.07% | 234 |
|
|
2026
Q1 | $79.2M | Buy |
1,261,461
+131,623
| +12% | +$10.5M | 0.41% | 42 |
|
|
2025
Q4 | $108M | Sell |
1,129,838
-117,633
| -9% | -$11.5M | 0.54% | 31 |
|
|
2025
Q3 | $122M | Buy |
1,247,471
+411,446
| +49% | +$42.6M | 0.64% | 28 |
|
|
2025
Q2 | $89.8M | Buy |
836,025
+421,213
| +102% | +$42.6M | 0.52% | 38 |
|
|
2025
Q1 | $42.1M | Buy |
414,812
+23,054
| +6% | +$2.32M | 0.26% | 91 |
|
|
2024
Q4 | $35M | Sell |
391,758
-83,157
| -18% | -$7.32M | 0.2% | 104 |
|
|
2024
Q3 | $39.8M | Buy |
474,915
+38,174
| +9% | +$3.01M | 0.23% | 99 |
|
|
2024
Q2 | $33.6M | Buy |
436,741
+13,730
| +3% | +$1M | 0.2% | 111 |
|
|
2024
Q1 | $29M | Sell |
423,011
-64,488
| -13% | -$4.15M | 0.19% | 123 |
|
|
2023
Q4 | $28.2M | Buy |
487,499
+43,268
| +10% | +$2.31M | 0.19% | 118 |
|
|
2023
Q3 | $23.5M | Buy |
444,231
+105,227
| +31% | +$5.52M | 0.17% | 122 |
|
|
2023
Q2 | $18.3M | Sell |
339,004
-73,721
| -18% | -$3.85M | 0.13% | 174 |
|
|
2023
Q1 | $19M | Buy |
412,725
+16,847
| +4% | +$794K | 0.13% | 171 |
|
|
2022
Q4 | $18.3M | Sell |
395,878
-43,458
| -10% | -$1.88M | 0.12% | 180 |
|
|
2022
Q3 | $17M | Buy |
439,336
+217,121
| +98% | +$8.71M | 0.12% | 186 |
|
|
2022
Q2 | $8.28M | Buy |
222,215
+146,361
| +193% | +$5.96M | 0.07% | 253 |
|
|
2022
Q1 | $3.36M | Buy |
75,854
+1,483
| +2% | +$64.3K | 0.02% | 431 |
|
|
2021
Q4 | $3.16M | Sell |
74,371
-8,821
| -11% | -$371K | 0.02% | 456 |
|
|
2021
Q3 | $3.61M | Buy |
83,192
+75
| +0.1% | +$3.32K | 0.02% | 457 |
|
|
2021
Q2 | $3.55M | Sell |
83,117
-3,216
| -4% | -$135K | 0.02% | 471 |
|
|
2021
Q1 | $2.98M | Hold |
86,333
| – | – | 0.02% | 457 |
|
|
2020
Q4 | $3.1M | Buy |
86,333
+11,133
| +15% | +$401K | 0.02% | 468 |
|
|
2020
Q3 | $2.87M | Sell |
75,200
-6,067
| -7% | -$234K | 0.03% | 446 |
|
|
2020
Q2 | $2.85M | Sell |
81,267
-20,286
| -20% | -$731K | 0.03% | 430 |
|
|
2020
Q1 | $4.49M | Hold |
101,553
| – | – | 0.05% | 377 |
|
|
2019
Q4 | $4.59M | Sell |
101,553
-5,464
| -5% | -$229K | 0.05% | 384 |
|
|
2019
Q3 | $4.36M | Buy |
107,017
+2,775
| +3% | +$118K | 0.06% | 347 |
|
|
2019
Q2 | $4.46M | Sell |
104,242
-5,851
| -5% | -$225K | 0.06% | 357 |
|
|
2019
Q1 | $4.23M | Buy |
110,093
+3,899
| +4% | +$149K | 0.05% | 358 |
|
|
2018
Q4 | $3.75M | Sell |
106,194
-2,791
| -3% | -$101K | 0.06% | 337 |
|
|
2018
Q3 | $4.2M | Hold |
108,985
| – | – | 0.06% | 357 |
|
|
2018
Q2 | $3.56M | Buy |
108,985
+5,132
| +5% | +$155K | 0.06% | 363 |
|
|
2018
Q1 | $2.84M | Hold |
103,853
| – | – | 0.05% | 403 |
|
|
2017
Q4 | $2.58M | Sell |
103,853
-3,613
| -3% | -$99.7K | 0.04% | 405 |
|
|
2017
Q3 | $3.13M | Buy |
107,466
+8,598
| +9% | +$237K | 0.05% | 367 |
|
|
2017
Q2 | $2.74M | Sell |
98,868
-244,564
| -71% | -$6.49M | 0.05% | 398 |
|
|
2017
Q1 | $8.54M | Sell |
343,432
-9,327
| -3% | -$227K | 0.17% | 160 |
|
|
2016
Q4 | $7.63M | Buy |
352,759
+287,004
| +436% | +$6.26M | 0.18% | 146 |
|
|
2016
Q3 | $1.56M | Buy |
65,755
+14,743
| +29% | +$352K | 0.04% | 405 |
|
|
2016
Q2 | $1.19M | Sell |
51,012
-205,076
| -80% | -$4.44M | 0.03% | 402 |
|
|
2016
Q1 | $4.79M | Buy |
256,088
+121,403
| +90% | +$2.13M | 0.12% | 202 |
|
|
2015
Q4 | $2.48M | Sell |
134,685
-2,810
| -2% | -$50.4K | 0.07% | 267 |
|
|
2015
Q3 | $2.26M | Sell |
137,495
-294,891
| -68% | -$5.04M | 0.06% | 320 |
|
|
2015
Q2 | $7.65M | Sell |
432,386
-831,266
| -66% | -$14.9M | 0.16% | 176 |
|
|
2015
Q1 | $22.4M | Sell |
1,263,652
-265,173
| -17% | -$4.19M | 0.45% | 54 |
|
|
2014
Q4 | $20.3M | Buy |
+1,528,825
| New | +$19.5M | 0.42% | 67 |
|
Other funds holding BSX
Candriam SCA's BSX Position: Q2 2026 in Review
Candriam SCA reduced its Boston Scientific (BSX) stake by 71% in Q2 2026, selling an estimated $48.5M and leaving 367,485 shares worth $15.7M. The position accounts for 0.07% of the portfolio, ranked #234.
Candriam SCA first reported a position in BSX in Q4 2014 and has held it in 47 quarters since. The position peaked at $122M in Q3 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Candriam SCA held 367,485 shares of Boston Scientific worth $15.7M as of Q2 2026.
- Candriam SCA sold 893,976 Boston Scientific shares in Q2 2026, an estimated $48.5M.
- Boston Scientific made up 0.07% of Candriam SCA's portfolio in Q2 2026, its #234 holding.
- Candriam SCA first reported a position in Boston Scientific in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Boston Scientific position peaked at $122M in Q3 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.